title: Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients.
abstract: OBJECTIVE
  This study aimed to evaluate the efficacy and safety of the treatment with (90)Y-ibritumomab tiuxetan following a short-course of rituximab with cyclophosphamide-adriamycin-vincristine-prednisone (R-CHOP) in high-risk elderly patients with previously untreated diffuse large B-cell lymphoma (DLBCL).
  
  
  METHODS
  From December 2006 to October 2008, 55 high-risk elderly (age > or =60 years) untreated DLBCL patients were treated in seven Italian institutions with a short-course of chemotherapy consisting of four cycles of R-CHOP21 followed by (90)Y-ibritumomab tiuxetan 6 to 10 weeks later.
  
  
  RESULTS
  Of the 55 patients, 48 underwent radioimmunotherapy. The overall response rate to the entire treatment regimen was 80%, including 73% complete remissions and 7% partial remissions. Eight (50%) of the 16 patients who achieved less than a complete response with CHOP improved their remission status after (90)Y-ibritumomab tiuxetan administration. With a median follow-up of 18 months, the 2-year progression-free survival was estimated to be 85%, with a 2-year overall survival of 86%. (90)Y-ibritumomab tiuxetan toxicity consisted of grade 3 to 4 hematologic toxicity in 28 of 48 patients, mainly neutropenia (23 patients) and thrombocytopenia (15 patients). Red cells and/or platelets transfusions were given to three patients.
  
  
  CONCLUSIONS
  This study evaluated the feasibility, efficacy, and safety of a short-course R-CHOP21 regimen followed by (90)Y-ibritumomab tiuxetan in high-risk elderly DLBCL patients.
authors.affiliation: Institute of Hematology and Medical Oncology L. e A. Seràgnoli, Policlinico Sant'Orsola-Malpighi, University of Bologna, Via Massarenti 9, Bologna, Italy. pierluigi.zinzani@unibo.it
authors.forename: Pier Luigi
authors.initials: PL
authors.lastname: Zinzani
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Rossi
authors.forename: Silvia
authors.initials: S
authors.lastname: Franceschetti
authors.forename: Barbara
authors.initials: B
authors.lastname: Botto
authors.forename: Alice
authors.initials: A
authors.lastname: Di Rocco
authors.forename: Maria Giuseppina
authors.initials: MG
authors.lastname: Cabras
authors.forename: Maria Concetta
authors.initials: MC
authors.lastname: Petti
authors.forename: Vittorio
authors.initials: V
authors.lastname: Stefoni
authors.forename: Alessandro
authors.initials: A
authors.lastname: Broccoli
authors.forename: Stefano
authors.initials: S
authors.lastname: Fanti
authors.forename: Cinzia
authors.initials: C
authors.lastname: Pellegrini
authors.forename: Gian Carlo
authors.initials: GC
authors.lastname: Montini
authors.forename: Letizia
authors.initials: L
authors.lastname: Gandolfi
authors.forename: Enrico
authors.initials: E
authors.lastname: Derenzini
authors.forename: Lisa
authors.initials: L
authors.lastname: Argnani
authors.forename: Mariapaola
authors.initials: M
authors.lastname: Fina
authors.forename: Alessandra
authors.initials: A
authors.lastname: Tucci
authors.forename: Chiara
authors.initials: C
authors.lastname: Bottelli
authors.forename: Stefano
authors.initials: S
authors.lastname: Pileri
authors.forename: Michele
authors.initials: M
authors.lastname: Baccarani
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects; D012307:Risk Factors; D000069283:Rituximab; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; C422802:ibritumomab tiuxetan; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone